Vir Biotechnology (NASDAQ:VIR) EVP Verneuil Vanina De Sells 3,117 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De sold 3,117 shares of the company’s stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $9.53, for a total transaction of $29,705.01. Following the completion of the sale, the executive vice president directly owned 126,682 shares in the company, valued at $1,207,279.46. This trade represents a 2.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Verneuil Vanina De also recently made the following trade(s):

• On Wednesday, February 25th, Verneuil Vanina De sold 13,700 shares of Vir Biotechnology stock. The shares were sold at an average price of $9.82, for a total transaction of $134,534.00.
• On Monday, February 23rd, Verneuil Vanina De sold 4,445 shares of Vir Biotechnology stock. The shares were sold at an average price of $7.45, for a total transaction of $33,115.25.

Vir Biotechnology Trading Down 6.8%

Shares of Vir Biotechnology stock traded down $0.68 during trading hours on Thursday, reaching $9.32. 21,297,575 shares of the company’s stock were exchanged, compared to its average volume of 3,752,478. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -2.95 and a beta of 1.69. The company has a fifty day moving average of $6.88 and a 200-day moving average of $6.02. Vir Biotechnology, Inc. has a 52-week low of $4.16 and a 52-week high of $10.94.

Vir Biotechnology (NASDAQ:VIR) last released its earnings results on Monday, February 23rd. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.11. Vir Biotechnology had a negative return on equity of 49.31% and a negative net margin of 638.88%.The firm had revenue of $64.07 million for the quarter, compared to the consensus estimate of $19.91 million. During the same period in the prior year, the business posted ($0.76) earnings per share. The firm’s revenue for the quarter was up 417.8% compared to the same quarter last year. On average, equities research analysts anticipate that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Trending Headlines about Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas collaboration materially derisks VIR‑5500 and adds near‑term cash/validation — the global co‑development/co‑commercialization deal includes significant upfront/near‑term payments and up to large milestone upside, boosting the program’s commercial outlook. Astellas and Vir Biotechnology collaborate on VIR-5500
• Positive Sentiment: Updated Phase 1 data for VIR‑5500 show encouraging safety and activity (notable higher‑dose response rates), supporting the asset value that underpins the Astellas deal. VIR-5500 Phase 1 results
• Positive Sentiment: Quarterly beat and revenue surge: Q4 EPS topped estimates and revenue (~$64.1M) far exceeded consensus, helping justify higher analyst targets and fueling recent upside. Vir Q4 earnings highlights
• Positive Sentiment: Analyst support: Needham and other firms raised targets/ratings after the results and deal news, reinforcing bullish institutional views. Needham raises VIR price target
• Neutral Sentiment: Management will be highly visible to investors in March (TD Cowen, Leerink) — useful for clarification on milestones, commercialization plans and cash use. Investor conference participation
• Neutral Sentiment: Media and valuation pieces are amplifying interest and volume — increased coverage raises visibility but doesn’t change fundamentals alone. Valuation after collaboration & Phase 1 update
• Negative Sentiment: Public offering priced: Vir priced 17,647,058 shares at $8.50 (gross proceeds about $150M). Proceeds bolster the balance sheet but the issuance is dilutive and can pressure the stock near term. Public offering priced
• Negative Sentiment: Clustered insider selling: Multiple insiders (CEO, EVPs, CFO, CAO, a director) reported stock sales across Feb. 23–25 — increases visible supply and can weigh on sentiment despite company progress. Insider selling report
• Negative Sentiment: Ongoing losses: Despite revenue growth and partnership cash, Vir reported a sizable net loss and wide negative margins — long‑term upside depends on execution, milestones and commercial ramp. 2025 financial results

Institutional Trading of Vir Biotechnology

Several large investors have recently bought and sold shares of VIR. Raymond James Financial Inc. acquired a new position in shares of Vir Biotechnology during the second quarter worth $35,000. FNY Investment Advisers LLC acquired a new position in Vir Biotechnology in the 3rd quarter worth $38,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Vir Biotechnology by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock valued at $41,000 after buying an additional 1,390 shares during the last quarter. UMB Bank n.a. grew its stake in shares of Vir Biotechnology by 1,418.7% during the fourth quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock valued at $43,000 after acquiring an additional 6,597 shares in the last quarter. Finally, Federated Hermes Inc. increased its position in shares of Vir Biotechnology by 153.8% during the third quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock worth $46,000 after acquiring an additional 4,899 shares during the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on VIR. Raymond James Financial raised shares of Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 price target on the stock in a research note on Tuesday. Evercore reiterated an “outperform” rating and issued a $18.00 target price on shares of Vir Biotechnology in a report on Tuesday. Needham & Company LLC boosted their price target on Vir Biotechnology from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Vir Biotechnology in a research note on Tuesday, December 30th. Finally, Morgan Stanley lifted their price objective on Vir Biotechnology from $20.00 to $24.00 and gave the company an “overweight” rating in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Vir Biotechnology currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.89.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.